Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephen Reddel

Showing results (11-20 of 41) with videos related to

Pageof 5
Sort By:
Journal of Neuroimmunology|December 26, 2013
Killer immunoglobulin-like receptor and their HLA ligands in Guillain-Barré SyndromeStefan Blum, Peter Csurhes, Stephen Reddel, et al.
Journal of Neurodegenerative Diseases|August 29, 2015
The MFN2 V705I Variant Is Not a Disease-Causing Mutation: A Segregation Analysis in a CMT2 FamilyObaid M Albulym, Danqing Zhu, Stephen Reddel, et al.
BMJ Neurology Open|June 6, 2022
Refractory <i>Mycobacterium genavense</i> infection secondary to thymoma-associated endogenous IL-12 inhibitorJessie Chen, MaiAnh Nguyen, Elaine Cheong, et al.
American Journal of Medical Genetics. Part A|October 3, 2023
ACBD5-related retinal dystrophy with leukodystrophy due to novel mutations in ACBD5 and with additional features including ovarian insufficiencyLaura Ivete Rudaks, James Triplett, Katrina Morris, et al.
Practical Neurology|April 14, 2018
<i>Actinomyces</i> cavernous sinus infection: a case and systematic literature reviewMichal Lubomski, James Dalgliesh, Kenneth Lee, et al.
Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia|May 30, 2015
Clinical features and impact of myasthenia gravis disease in Australian patientsStefan Blum, David Lee, David Gillis, et al.
Practical Neurology|August 3, 2024
Immunoglobulin use in neurology: a practical approachMahima Kapoor, Anthony Khoo, Michael P T Lunn, et al.
Therapeutic Advances in Neurological Disorders|April 11, 2019
Risks and risk management in modern multiple sclerosis immunotherapeutic treatmentLuisa Klotz, Joachim Havla, Nicholas Schwab, et al.
Therapeutic Advances in Neurological Disorders|April 3, 2023
Comparison of IVIg and TPE efficacy in the treatment of neurological disorders: a systematic literature reviewAshwin A Pinto, Jerome De Seze, Anu Jacob, et al.
The Journal of Biological Chemistry|November 17, 2001
Heparin inhibits the binding of beta 2-glycoprotein I to phospholipids and promotes the plasmin-mediated inactivation of this blood protein. Elucidation of the consequences of the two biological events in patients with the anti-phospholipid syndromeJan Guerin, Yonghua Sheng, Stephen Reddel, et al.
Pageof 5

Showing results (11-20 of 41) with videos related to

Sort By:
Pageof 5
Journal of Neuroimmunology|December 26, 2013
Killer immunoglobulin-like receptor and their HLA ligands in Guillain-Barré SyndromeStefan Blum, Peter Csurhes, Stephen Reddel, et al.
Journal of Neurodegenerative Diseases|August 29, 2015
The MFN2 V705I Variant Is Not a Disease-Causing Mutation: A Segregation Analysis in a CMT2 FamilyObaid M Albulym, Danqing Zhu, Stephen Reddel, et al.
BMJ Neurology Open|June 6, 2022
Refractory <i>Mycobacterium genavense</i> infection secondary to thymoma-associated endogenous IL-12 inhibitorJessie Chen, MaiAnh Nguyen, Elaine Cheong, et al.
American Journal of Medical Genetics. Part A|October 3, 2023
ACBD5-related retinal dystrophy with leukodystrophy due to novel mutations in ACBD5 and with additional features including ovarian insufficiencyLaura Ivete Rudaks, James Triplett, Katrina Morris, et al.
Practical Neurology|April 14, 2018
<i>Actinomyces</i> cavernous sinus infection: a case and systematic literature reviewMichal Lubomski, James Dalgliesh, Kenneth Lee, et al.
Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia|May 30, 2015
Clinical features and impact of myasthenia gravis disease in Australian patientsStefan Blum, David Lee, David Gillis, et al.
Practical Neurology|August 3, 2024
Immunoglobulin use in neurology: a practical approachMahima Kapoor, Anthony Khoo, Michael P T Lunn, et al.
Therapeutic Advances in Neurological Disorders|April 11, 2019
Risks and risk management in modern multiple sclerosis immunotherapeutic treatmentLuisa Klotz, Joachim Havla, Nicholas Schwab, et al.
Therapeutic Advances in Neurological Disorders|April 3, 2023
Comparison of IVIg and TPE efficacy in the treatment of neurological disorders: a systematic literature reviewAshwin A Pinto, Jerome De Seze, Anu Jacob, et al.
The Journal of Biological Chemistry|November 17, 2001
Heparin inhibits the binding of beta 2-glycoprotein I to phospholipids and promotes the plasmin-mediated inactivation of this blood protein. Elucidation of the consequences of the two biological events in patients with the anti-phospholipid syndromeJan Guerin, Yonghua Sheng, Stephen Reddel, et al.
Pageof 5